Cubbon Richard M, Wheatcroft Stephen B, Grant Peter J, Gale Christopher P, Barth Julian H, Sapsford Robert J, Ajjan Ramzi, Kearney Mark T, Hall Alistair S
Leeds Institute of Genetics, Health, and Therapeutics, The LIGHT Laboratories, Clarendon Way, Leeds LS2 9JT, UK.
Eur Heart J. 2007 Mar;28(5):540-5. doi: 10.1093/eurheartj/ehl510. Epub 2007 Feb 8.
Over the last decade, advances in treatment for patients sustaining an acute myocardial infarction (AMI) have reduced mortality rates. We aimed to assess whether patients with diabetes mellitus (DM) have derived similar benefits as patients without DM.
We compared characteristics, management, and survival of patients with and without DM who sustained an AMI in 1995 (n = 1762) with a second group of patients who sustained an AMI in 2003 (n = 1642). All patients were followed up for 18 months or until death. Between 1995 and 2003 the prevalence of DM in AMI patients increased from 12.5 to 16.6% (P < 0.001). Involvement of cardiologists, provision of secondary prevention agents and early revascularization rates improved in both groups. Thirty-day mortality improved significantly in patients with and without DM [40% (P = 0.006) and 30% (P < 0.001) relative reductions, respectively]. Despite this, there was no significant change in mortality at 18 months in patients with DM when comparing 1995 and 2003 (absolute mortality 38.0 vs. 36.4%, P = 0.71). The interaction between DM and study period in predicting long-term mortality was highly significant (P = 0.008); this persisted after adjustment for baseline characteristics and treatment variables.
Although early post-AMI mortality has fallen in patients with and without DM, these improvements were only maintained in the longer term in those without DM; more effective diabetes-related management strategies are required post-AMI.
在过去十年中,急性心肌梗死(AMI)患者的治疗进展降低了死亡率。我们旨在评估糖尿病(DM)患者是否与非糖尿病患者获得了相似的益处。
我们比较了1995年发生AMI的糖尿病患者和非糖尿病患者(n = 1762)与2003年发生AMI的另一组患者(n = 1642)的特征、治疗和生存率。所有患者均随访18个月或直至死亡。1995年至2003年期间,AMI患者中DM的患病率从12.5%升至16.6%(P < 0.001)。两组中,心脏病专家的参与、二级预防药物的提供以及早期血运重建率均有所改善。糖尿病患者和非糖尿病患者的30天死亡率均显著改善[相对降低分别为40%(P = 0.006)和30%(P < 0.001)]。尽管如此,比较1995年和2003年时,糖尿病患者18个月时的死亡率并无显著变化(绝对死亡率38.0%对36.4%,P = 0.71)。DM与研究时期在预测长期死亡率方面的相互作用非常显著(P = 0.008);在对基线特征和治疗变量进行调整后,这种情况依然存在。
尽管AMI后早期死亡率在糖尿病患者和非糖尿病患者中均有所下降,但这些改善仅在非糖尿病患者中长期维持;AMI后需要更有效的糖尿病相关管理策略。